Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
Humans
Female
Middle Aged
Breast Neoplasms
/ drug therapy
Fulvestrant
/ therapeutic use
Retrospective Studies
Receptor, ErbB-2
/ genetics
Hyperglycemia
/ prevention & control
Risk Factors
Class I Phosphatidylinositol 3-Kinases
/ genetics
EGF Family of Proteins
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Alpelisib
Hormone-receptor positive
Hyperglycemia
Metastatic breast cancer
PIK3CA
Rash
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
23
06
2022
accepted:
03
11
2022
pubmed:
22
11
2022
medline:
11
1
2023
entrez:
21
11
2022
Statut:
ppublish
Résumé
SOLAR-1 investigated alpelisib-fulvestrant (ALP + FLV) in patients with HR + /HER2-, PIK3CA-mutated advanced breast cancer and demonstrated a clinically significant increase in all-grade and grade (G) 3-4 hyperglycemia (HG) compared to placebo-fulvestrant. Given high rates of HG, a preventative protocol and identification of associated risk factors was implemented. This single-center, retrospective study included patients receiving ALP + FLV. One week before ALP initiation, patients started an insulin-sensitizer. Patients had fasting plasma glucose (FPG) levels drawn day 8, 15, 28, then monthly. Primary outcome was incidence of G2-4 HG by day 28. Risk factors assessed included age, BMI, FPG, and HbA1c. Number of risk factors were compared between patients with and without HG. Sixteen women were included with median age of 59 years. The cohort was 69% White, 25% Black, 75% with BMI ≥ 25 kg/m Implementation of a HG prophylaxis protocol with ALP in a single-center study demonstrated fewer G3-4 HG events compared to that seen in SOLAR-1 (19% vs 36.6%). An increase in HG-associated risk factors correlated with a higher incidence of G2-4 HG.
Identifiants
pubmed: 36409396
doi: 10.1007/s10549-022-06798-8
pii: 10.1007/s10549-022-06798-8
doi:
Substances chimiques
Fulvestrant
22X328QOC4
Alpelisib
08W5N2C97Q
Receptor, ErbB-2
EC 2.7.10.1
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
EGF Family of Proteins
0
PIK3CA protein, human
EC 2.7.1.137
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
369-376Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Siegel RL, Miller KD, Jemal A (2020) Cancer Statistics, 2020. CA Cancer J Clin 70:7–30
doi: 10.3322/caac.21590
American Cancer Society (2019) Breast cancer facts & figures 2019–2020. American Cancer Society, Inc., Atlanta
National Comprehensive Cancer Network. Breast Cancer (Version 5.2020). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . Accessed 26 July 2020
Network CGA (2012) Comprehensive molecular portraits of human breast tumors. Nature 490(7418):61–70. https://doi.org/10.1038/nature11412
doi: 10.1038/nature11412
Ellis H, Ma CX (2019) PI3K inhibitors in breast cancer therapy. Curr Oncol Rep 21(110):1–9. https://doi.org/10.1007/s11912-019-0846-7
doi: 10.1007/s11912-019-0846-7
Piqray (alpelisib) (2019) [prescribing information]. Novartis Pharmaceuticals Corporation, East Hanover
Andre F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929–1940. https://doi.org/10.1056/NEJMoa1813904
doi: 10.1056/NEJMoa1813904
Dullinsky PR, Hurvitz SA (2020) Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Res Treat 181:233–248. https://doi.org/10.1007/s10549-020-05618-1
doi: 10.1007/s10549-020-05618-1
Rugo HS, Andre F, Yamashita T et al (2020) Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 31(8):1001–1010. https://doi.org/10.1016/j.annonc.2020.05.001
doi: 10.1016/j.annonc.2020.05.001
Hopkins BD, Pauli C, Du X et al (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499–503. https://doi.org/10.1038/s41586-018-0343-4
doi: 10.1038/s41586-018-0343-4
American Diabetes Association (2021) Classification and diagnosis of diabetes: Standards of medical care in diabetes—2021. Diabetes Care 44(Supplement 1):S15–S33. https://doi.org/10.2337/dc21-S002
doi: 10.2337/dc21-S002
Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 95:103208. https://doi.org/10.1016/j.jbi.2019.103208
doi: 10.1016/j.jbi.2019.103208
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. https://doi.org/10.1016/j.jbi.2008.08.010
doi: 10.1016/j.jbi.2008.08.010
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Published: May 28, 2009. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute
Rugo HS, Lerebours F, Ciruelos E et al (2021) Aplelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 22(4):489–498. https://doi.org/10.1016/S1470-2045(21)00034-6
doi: 10.1016/S1470-2045(21)00034-6
Kawahito S, Kitahata H, Oshita S (2009) Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 15:4137–4142. https://doi.org/10.3748/wjg.15.4137
doi: 10.3748/wjg.15.4137
American Diabetes Association (2021) Glycemic targets: Standards of medical care in diabetes—2021. Diabetes Care 44(Supplement 1):S73–S84. https://doi.org/10.2337/dc21-S006
doi: 10.2337/dc21-S006
American Diabetes Association (2021) Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2021. Diabetes Care 44(Supplement 1):S111–S124. https://doi.org/10.2337/dc21-S009
doi: 10.2337/dc21-S009
Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (EPIK-B4). ClinicalTrials.gov identifier: NCT04899349. Updated December 7, 2021. Accessed 28 Jan 2022. https://clinicaltrials.gov/ct2/show/NCT04899349 .